IP Library › Granted Patent US 12,202,878
Granted Patent B2
US 12,202,878 · App. 17/832,290 · Granted Jan 21, 2025

Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods

Inventors: Heiko Schuster (Tuebingen, DE); Daniel Johannes Kowalewski (Tuebingen, DE); Oliver Schoor (Tuebingen, DE); Jens Fritsche (Tuebingen, DE); Toni Weinschenk (Tuebingen, DE); Harpreet Singh (Tuebingen, DE); Gisela Schimmack (Tuebingen, DE); Michael Roemer (Tuebingen, DE)
Assignee: Immatics Biotechnologies GmbH
C07K14/7051A61K9/19A61K35/17A61K39/0011A61K39/001111A61K39/4611A61K39/4644A61P35/00C07K14/70539C07K16/2809C07K16/2833C12N5/0636C12N5/0638C12N15/115G01N33/57492G16B25/10A61K38/00C07K2319/00C12N2310/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,202,878
App. No.
17/832,290
Granted
Jan 21, 2025
Kind
B2
Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Claims (20)

1. A peptide consisting of the amino acid sequence LPQLKPAL (SEQ ID NO: 22) in the form of a pharmaceutically acceptable salt.

2. The peptide of claim 1 , wherein said peptide has the ability to bind to an MHC class-I molecule, and wherein said peptide, when bound to said MHC, is capable of being recognized by CD8 T cells.

3. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is chloride salt.

4. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is acetate salt.

5. A composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.

6. The composition of claim 5 , wherein the peptide is in the form of a chloride salt.

7. The composition of claim 5 , wherein the peptide is in the form of an acetate salt.

8. The composition of claim 5 , further comprising an adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

9. The composition of claim 8 , wherein the adjuvant is IL-2.

10. The composition of claim 8 , wherein the adjuvant is IL-7.

11. The composition of claim 8 , wherein the adjuvant is IL-12.

12. The composition of claim 8 , wherein the adjuvant is IL-15.

13. The composition of claim 8 , wherein the adjuvant is IL-21.

14. A pegylated peptide consisting of the amino acid sequence of LPQLKPAL (SEQ ID NO: 22) or a pharmaceutically acceptable salt thereof.

15. The peptide of claim 14 , wherein the pharmaceutically acceptable salt is chloride salt.

16. The peptide of claim 14 , wherein the pharmaceutically acceptable salt is acetate salt.

17. A composition comprising the pegylated peptide of claim 14 or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

18. The peptide in the form of a pharmaceutically acceptable salt of claim 1 , wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.

19. A composition comprising the peptide of claim 1 , wherein the composition is a pharmaceutical composition and comprises water and a buffer.

20. A peptide consisting of the amino acid sequence LPQLKPAL (SEQ ID NO: 22) in the form of a salt.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2022
From: SCHUSTER, HEIKO; KOWALEWSKI, DANIEL JOHANNES; SCHOOR, OLIVER; FRITSCHE, JENS; WEINSCHENK, TONI; SINGH, HARPREET; SCHIMMACK, GISELA; ROEMER, MICHAEL
To: IMMATICS BIOTECHNOLOGIES GMBH
Reel/Frame 060213/0035 →
Priority Claims (2)
DE 102018118550.2 · Jul 31, 2018 · national
DE 102018119555.9 · Aug 10, 2018 · national
Continuity (5)
Continuation 17472290 · Sep 10, 2021
Continuation 16526114 · Jul 30, 2019
Provisional Application 62717462 · Aug 10, 2018
Provisional Application 62712691 · Jul 31, 2018
Related Publication 20220324941A1 · Oct 13, 2022
References Cited (170)
US 7807642B2 · Dengjel · 2010 [cited by applicant]
US 7833969B2 · Dengjel · 2010 [cited by applicant]
US 7833970B2 · Dengjel · 2010 [cited by applicant]
US 9802997B2 · Mahr et al. · 2017 [cited by applicant]
US 9840548B2 · Mahr et al. · 2017 [cited by applicant]
US 9862756B2 · Mahr et al. · 2018 [cited by applicant]
US 9908920B2 · Mahr et al. · 2018 [cited by applicant]
US 9932384B2 · Mahr et al. · 2018 [cited by applicant]
US 9951119B2 · Mahr et al. · 2018 [cited by applicant]
US 9982030B2 · Mahr et al. · 2018 [cited by applicant]
US 9982031B2 · Mahr et al. · 2018 [cited by applicant]
US 9988432B2 · Mahr et al. · 2018 [cited by applicant]
US 9993539B2 · Mahr et al. · 2018 [cited by applicant]
US 9994628B2 · Mahr et al. · 2018 [cited by applicant]
US 10000547B2 · Mahr et al. · 2018 [cited by applicant]
US 10005828B2 · Mahr et al. · 2018 [cited by applicant]
US 10059755B2 · Mahr et al. · 2018 [cited by applicant]
US 10066003B1 · Mahr et al. · 2018 [cited by applicant]
US 10072063B2 · Mahr et al. · 2018 [cited by applicant]
US 10081664B2 · Mahr et al. · 2018 [cited by applicant]
US 10081665B2 · Mahr et al. · 2018 [cited by applicant]
US 10093715B2 · Mahr et al. · 2018 [cited by applicant]
US 10106593B2 · Mahr et al. · 2018 [cited by applicant]
US 10106594B2 · Mahr et al. · 2018 [cited by applicant]
US 10131703B2 · Mahr et al. · 2018 [cited by applicant]
US 10138288B2 · Mahr et al. · 2018 [cited by applicant]
US 10155032B2 · Mahr et al. · 2018 [cited by applicant]
US 10155801B1 · Mahr et al. · 2018 [cited by applicant]
US 10183982B2 · Mahr et al. · 2019 [cited by applicant]
US 10196422B2 · Rammensee · 2019 [cited by applicant]
US 10196432B2 · Dengiel · 2019 [cited by applicant]
US 10202436B2 · Mahr et al. · 2019 [cited by applicant]
US 10238727B2 · Mahr et al. · 2019 [cited by applicant]
US 10336809B2 · Mahr et al. · 2019 [cited by applicant]
US 10370429B2 · Mahr et al. · 2019 [cited by applicant]
US 10376568B2 · Mahr et al. · 2019 [cited by applicant]
US 10377797B2 · Rammensee · 2019 [cited by applicant]
US 10383930B2 · Mahr et al. · 2019 [cited by applicant]
US 10449238B2 · Mahr et al. · 2019 [cited by applicant]
US 10450362B2 · Mahr et al. · 2019 [cited by applicant]
US 10478480B2 · Mahr et al. · 2019 [cited by applicant]
US 10479823B2 · Mahr et al. · 2019 [cited by applicant]
US 10487131B2 · Mahr et al. · 2019 [cited by applicant]
US 10500259B2 · Mahr et al. · 2019 [cited by applicant]
US 10501522B2 · Mahr et al. · 2019 [cited by applicant]
US 10519215B2 · Mahr et al. · 2019 [cited by applicant]
US 10532091B1 · Mahr et al. · 2020 [cited by applicant]
US 10618945B2 · Dengjel · 2020 [cited by applicant]
US 10723781B2 · Mahr et al. · 2020 [cited by applicant]
US 10766944B2 · Mahr et al. · 2020 [cited by applicant]
US 10799569B2 · Mahr et al. · 2020 [cited by applicant]
US 10934338B2 · Mahr et al. · 2021 [cited by applicant]
US 10947293B2 · Mahr et al. · 2021 [cited by applicant]
US 10947294B2 · Mahr et al. · 2021 [cited by applicant]
US 11058754B2 · Mahr et al. · 2021 [cited by applicant]
US 11065315B2 · Mahr et al. · 2021 [cited by applicant]
US 11155597B2 · Mahr et al. · 2021 [cited by applicant]
US 11407807B2 · Mahr et al. · 2022 [cited by applicant]
US 11466072B2 · Mahr et al. · 2022 [cited by applicant]
US 11655281B2 · Schuster · 2023 [cited by examiner]
US 11702460B2 · Mahr et al. · 2023 [cited by applicant]
US 11732021B2 · Schuster et al. · 2023 [cited by applicant]
US 11873329B2 · Mahr et al. · 2024 [cited by applicant]
US 11897934B2 · Mahr et al. · 2024 [cited by applicant]
US 20070009433A1 · Meyers et al. · 2007 [cited by applicant]
US 20070020327A1 · Fikes et al. · 2007 [cited by applicant]
US 20080113344A1 · Wirtz et al. · 2008 [cited by applicant]
US 20080206216A1 · Dengjel · 2008 [cited by applicant]
US 20120077696A1 · Admon et al. · 2012 [cited by applicant]
US 20160061817A1 · Xian · 2016 [cited by applicant]
US 20160279214A1 · Mahr et al. · 2016 [cited by applicant]
US 20160279215A1 · Mahr et al. · 2016 [cited by applicant]
US 20160279216A1 · Mahr et al. · 2016 [cited by applicant]
US 20160279217A1 · Mahr et al. · 2016 [cited by applicant]
US 20160279218A1 · Mahr et al. · 2016 [cited by applicant]
US 20160280738A1 · Mahr et al. · 2016 [cited by applicant]
US 20160280752A1 · Mahr et al. · 2016 [cited by applicant]
US 20160280757A1 · Mahr et al. · 2016 [cited by applicant]
US 20160280758A1 · Mahr et al. · 2016 [cited by applicant]
US 20160280759A1 · Mahr et al. · 2016 [cited by applicant]
US 20160280760A1 · Mahr et al. · 2016 [cited by applicant]
US 20170022251A1 · Rammensee · 2017 [cited by applicant]
US 20170037089A1 · Mahr · 2017 [cited by examiner]
US 20170145072A1 · Mahr et al. · 2017 [cited by applicant]
US 20170145073A1 · Mahr et al. · 2017 [cited by applicant]
US 20170158750A1 · Mahr et al. · 2017 [cited by applicant]
US 20170305992A1 · Mahr et al. · 2017 [cited by applicant]
US 20170305993A1 · Mahr et al. · 2017 [cited by applicant]
US 20170313760A1 · Mahr et al. · 2017 [cited by applicant]
US 20180030113A1 · Mahr et al. · 2018 [cited by applicant]
US 20180037626A1 · Mahr et al. · 2018 [cited by applicant]
US 20180037627A1 · Mahr et al. · 2018 [cited by applicant]
US 20180037628A1 · Mahr et al. · 2018 [cited by applicant]
US 20180037629A1 · Mahr et al. · 2018 [cited by applicant]
US 20180094043A1 · Mahr et al. · 2018 [cited by applicant]
US 20180141993A1 · Mahr et al. · 2018 [cited by applicant]
US 20180153975A1 · Fritsch et al. · 2018 [cited by applicant]
US 20180208640A1 · Mahr et al. · 2018 [cited by applicant]
US 20180208641A1 · Mahr et al. · 2018 [cited by applicant]
US 20180230194A1 · Mahr et al. · 2018 [cited by applicant]
US 20180230195A1 · Mahr et al. · 2018 [cited by applicant]
US 20180237493A1 · Mahr et al. · 2018 [cited by applicant]
US 20180237494A1 · Mahr et al. · 2018 [cited by applicant]
US 20180251517A1 · Mahr et al. · 2018 [cited by applicant]
US 20180251518A1 · Mahr et al. · 2018 [cited by applicant]
US 20180258155A1 · Mahr et al. · 2018 [cited by applicant]
US 20180327475A1 · Mahr et al. · 2018 [cited by applicant]
US 20180340019A1 · Mahr et al. · 2018 [cited by applicant]
US 20180346548A1 · Mahr et al. · 2018 [cited by applicant]
US 20190002524A1 · Mahr et al. · 2019 [cited by applicant]
US 20190023762A1 · Mahr et al. · 2019 [cited by applicant]
US 20190077832A1 · Rammensee · 2019 [cited by applicant]
US 20190119351A1 · Mahr et al. · 2019 [cited by applicant]
US 20190119352A1 · Mahr et al. · 2019 [cited by applicant]
US 20190185540A1 · Mahr et al. · 2019 [cited by applicant]
US 20200024325A1 · Mahr et al. · 2020 [cited by applicant]
US 20200031899A1 · Mahr et al. · 2020 [cited by applicant]
US 20200040060A1 · Mahr et al. · 2020 [cited by applicant]
US 20200087378A1 · Mahr et al. · 2020 [cited by applicant]
US 20200308250A1 · Mahr et al. · 2020 [cited by applicant]
US 20200325206A1 · Mahr et al. · 2020 [cited by applicant]
US 20210061914A1 · Jooss et al. · 2021 [cited by applicant]
US 20210179691A1 · Mahr et al. · 2021 [cited by applicant]
US 20210188943A1 · Mahr et al. · 2021 [cited by applicant]
US 20210188944A1 · Mahr et al. · 2021 [cited by applicant]
US 20210275653A1 · Mahr et al. · 2021 [cited by applicant]
US 20210275654A1 · Mahr et al. · 2021 [cited by applicant]
US 20210283230A1 · Mahr et al. · 2021 [cited by applicant]
US 20220002374A1 · Schuster et al. · 2022 [cited by applicant]
US 20220009995A1 · Mahr et al. · 2022 [cited by applicant]
US 20220125902A1 · Mahr et al. · 2022 [cited by applicant]
US 20220133870A1 · Mahr et al. · 2022 [cited by applicant]
US 20220143162A1 · Mahr et al. · 2022 [cited by applicant]
US 20220143163A1 · Mahr et al. · 2022 [cited by applicant]
US 20220143164A1 · Mahr et al. · 2022 [cited by applicant]
US 20220152171A1 · Mahr et al. · 2022 [cited by applicant]
US 20220152175A1 · Mahr et al. · 2022 [cited by applicant]
EP 1760088B1 · 2008 [cited by applicant]
TW 201700496A · 2017 [cited by applicant]
WO 03040165A2 · 2003 [cited by applicant]
WO 2007028574A2 · 2007 [cited by applicant]
WO 2015193359A2 · 2015 [cited by applicant]
WO 2016172722A1 · 2016 [cited by applicant]
WO 2016207164A2 · 2016 [cited by applicant]
WO 2017021527A2 · 2017 [cited by applicant]
WO 2019133853A1 · 2019 [cited by applicant]
International Search Report issued in PCT/EP2019/070430, mailed Dec. 16, 2019. [cited by applicant]
Christos K. Kontos et al., “Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers”, Clinical Chemistry and Laboratory Medicine, vol. 50, No. 11, (Jan. 1, 2012), XP055627910, DE ISSN: 1434-6621, … [cited by applicant]
Adamopoulos Panagiotis et al., “Discovery of novel transcripts of the human tissue kallikrein (KLKI) and kallikrein-related peptidase 2 (KLK2) in human cancer cells, exploiting Next-Generation Sequencing technology”, Ge… [cited by applicant]
Janeway CA Jr, Travers P, Walport M, et al., (Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. Antigen recognition by T cells. Available from: https://www.ncbi.nlm.ni… [cited by applicant]
Li, et al., “Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cells,” Oncotarget, 7(51), pp. 84645-84657 (Dec. 20, 2016). [cited by applicant]
Pritchard, et al., “Exploration of peptides bound to MHC class I molecules in melanoma,” Pigment Cell Melanoma Res., v28(3); pp. 281-294 (May 2015). [cited by applicant]
Beatty, Gregory L., et al. “IFN-g-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD41 T Cells Requires Tumor Responsiveness to IFN-y1” Journal of Immunology, vol. 166, No. 4, pp. 2276-2282, Feb. 15, 20… [cited by applicant]
Bray, Freddie, et al. “Global estimates of cancer prevalence for 27 sites in the adult population in 2008” International Journal of Cancer, vol. 132, pp. 1133-1145, 2013. [cited by applicant]
Brossart, Peter and Bevan, Michael J. “Presentation of Exogenous Protein Antigens on Major Histocompatability Complex Class I Molecules by Dendritic Cells: Pathway of Presentation and Regulation by Cytokines” Blood, vol… [cited by applicant]
Dengjel, Joern, et al. “Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas” Clinical Cancer Research, vol. 12, No. 14, pp. 4163-4170, Jul. 15, 2006. [cited by applicant]
Ferlay, J., et al. “Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012” European Journal of Cancer, vol. 49, pp. 1374-1403, Apr. 2013. [cited by applicant]
Gnjatic, Sacha, et al. “Survey of naturally occurring CD4 T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses” PNAS, vol. 100, No. 15, pp. 8862-8867, Jul. 22, 2003. [cited by applicant]
Gunawardana, Chaminda, et al. “South Asian chronic lymphocytic leukaemia patients have more rapid disease progression in comparison to White patients” British Journal of Haematology, vol. 142, pp. 606-609, May 2008. [cited by applicant]
Hwang. Melissa L., et al. “Cognate memory CD4+ T cells generated with dendritic cell priming influence the expansion, trafficking, and differentiation of secondary CD8+ T cells and enhance tumor control” Journal of Immu… [cited by applicant]
Molina, Julian R., et al. “Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship” Mayo Clinic Proceedings, vol. 83, No. 5m pp. 584-594, May 2008. [cited by applicant]
Mortara, Lorenzo, et al. “CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory” Clinical Cancer Researc… [cited by applicant]
Mumberg et al., “Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds,” Gene 156(1):119-22 (1995). [cited by applicant]
Rock, K.L., et al. “Presentation of exogenous antigen with class I major histocompatibility complex molecules” Science, vol. 249, No. 4971, pp. 918-921, Aug. 1990. [cited by applicant]
Singh-Jasuja, Harpreet et al. “!The Tuebingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy” Cancer Immunology, Immunotherapy, vol. 53, pp. 187-185, Jan. 2004. [cited by applicant]
Thakkar, Jigisha P., et al. “Epidemiologic and Molecular Prognostic Review of Glioblastoma” Cancer Epidemiol. Biomarkers Prev. vol. 23, No. 10, pp. 1985-1996, Oct. 2014. [cited by applicant]
Hassan et al.,“The human leukocyte antigen-presented ligandome of B lymphocytes.” Molecular & Cellular Proteomics 12, No. 7 (2013): 1829-1843. [cited by applicant]
Hassan et al., “Naturally processed non-canonical HLA-A* 02: 01 presented peptides” The Journal of Biological Chemistry vol. 290, No. 5, pp. 2593-2603, Jan. 30, 2015. [cited by applicant]
Löffler et al., “Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient.” Journal of hepatology 65, No. 4 (2016): 849-855. [cited by applicant]
Neidert et al., “The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.” Acta neuropathologica 135 (2018): 923-938. [cited by applicant]